QUESTIONS TO ASK BEFORE
AUTOIMMUNE CAR-T THERAPY

Most severe autoimmune diseases are driven by autoreactive B cells that produce pathogenic autoantibodies. Anti-CD19 CAR-T eliminates the entire B-cell compartment — including autoreactive clones — and creates a window of immune reset before B cells repopulate.

• The Schett Group — Landmark Cases

  Professor Georg Schett and colleagues at Friedrich-Alexander University Erlangen-Nürnberg (Germany) published the first series of anti-CD19 CAR-T cases in autoimmune disease: SLE, inflammatory myositis (anti-synthetase syndrome), and systemic sclerosis. Multiple patients achieved drug-free remission — unprecedented for these conditions.

• Diseases Showing Response

  Published evidence covers: systemic lupus erythematosus (SLE), myasthenia gravis (MG), anti-synthetase syndrome, systemic sclerosis (scleroderma), and mixed connective tissue disease. All involve autoreactive B cells and autoantibodies as key pathogenic drivers.

• Still Investigational

  Autoimmune CAR-T is not commercially approved anywhere as of 2026. It is delivered under clinical trial, compassionate use, or academic protocols. Patients must meet specific criteria and are evaluated individually by the treating team.

• China's Emerging Role

  Chinese centres — including at Peking Union Medical College Hospital (PUMCH) and Shanghai centres — are beginning to enrol autoimmune patients in anti-CD19 and CD19+CD20 dual CAR-T trials. CancerFax monitors trial status and can facilitate access reviews.

Eligibility for autoimmune CAR-T depends on disease severity, prior treatment failure, and organ function — similar to but distinct from cancer CAR-T eligibility.

• Q1: Am I eligible for autoimmune CAR-T?

  Eligibility typically requires: severe, refractory disease that has failed at least 2–3 standard immunosuppressive regimens; active autoantibody or B-cell-driven pathology; adequate organ function; and no active infection. Ask your rheumatologist to assess your case against published Schett-protocol criteria.

• Q2: Which disease target applies to my condition?

  Anti-CD19 CAR-T is the primary construct studied for SLE, MG, and scleroderma — these diseases are driven by CD19+ B cells and plasmablasts. Your disease must have a B-cell-dependent mechanism. Pure T-cell-driven autoimmunity (e.g., certain vasculitides) may not benefit from CD19 targeting.

• Q3: Is this a clinical trial or compassionate access?

  Most autoimmune CAR-T is delivered under a registered clinical trial protocol. Compassionate use is available in some centres for patients who do not meet strict trial inclusion criteria but have life-threatening disease. Ask the centre specifically which pathway applies to you and what regulatory oversight governs it.

The risk profile of CAR-T in autoimmune disease differs meaningfully from cancer CAR-T — patients are generally younger and healthier, but some risks are specific to the autoimmune context.

• Q4: What are the specific risks of CAR-T in my autoimmune disease?

  Key risks include: (1) infection during B-cell aplasia — more significant in autoimmune patients who are often chronically immunosuppressed; (2) hypogammaglobulinaemia requiring IVIG replacement for 6–12 months; (3) disease flare during or after CAR-T — paradoxical worsening before improvement; and (4) CRS, which is generally milder in autoimmune CAR-T than in cancer CAR-T.

• Q5: How does CAR-T compare to rituximab or cyclophosphamide for my disease?

  Rituximab and cyclophosphamide deplete B cells partially and temporarily. CAR-T produces a deeper and more sustained B-cell depletion — including tissue-resident B cells and long-lived plasmablasts. In published cases, CAR-T achieved remissions that rituximab had not. Ask: has my disease failed rituximab? If yes, CAR-T may offer something different.

• Q6: How long until remission might be seen?

  In published autoimmune CAR-T cases, clinical improvement began 2–8 weeks after infusion, with autoantibody titers (ANA, anti-dsDNA, anti-AChR) falling within 4–12 weeks. Drug-free clinical remission was achieved in several Schett-series patients within 3–6 months. Timeline varies by disease — MG appears to respond particularly rapidly.

Three further questions that patients frequently ask — and which have distinct answers in the autoimmune context.

• Q7: Will my autoimmune disease come back?

  Relapse is possible when B cells repopulate. In the Schett series, some patients maintained drug-free remission beyond 2 years. Others experienced mild disease return managed with standard agents. The goal is a prolonged window of remission — potentially enabling steroid and immunosuppressant withdrawal — even if disease returns later.

• Q8: What monitoring is needed after CAR-T?

  Monthly monitoring for the first 6 months: CBC for cytopenia, IgG for hypogammaglobulinaemia (IVIG threshold), autoantibody levels (disease-specific), and disease activity scores (SLEDAI, MG-ADL etc.). Long-term: 3-monthly monitoring until B-cell recovery. Ongoing immune reconstitution assessment is important.

• Q9: What about fertility and pregnancy?

  Lymphodepletion chemotherapy (fludarabine and cyclophosphamide) carries gonadotoxicity risk. Female patients of childbearing age should consider fertility preservation (egg/embryo cryopreservation) before lymphodepletion. Male patients should consider sperm banking. Pregnancy is contraindicated during and for at least 12 months after CAR-T therapy.

Access to autoimmune CAR-T is the most practical challenge patients face. Options are expanding but still limited to a small number of specialist centres globally.

• Q10: Where Can I Access Autoimmune CAR-T?

  Germany (Erlangen — academic, Schett group); USA (academic centres — trial dependent); China (PUMCH Beijing and Shanghai centres — emerging trials 2025–2026). CancerFax monitors active enrolment and can advise on the current most accessible option by nationality and disease.

• Q11: How Does CancerFax Help?

  CancerFax reviews your autoimmune disease history, autoantibody profile, prior treatment lines, and organ function. We identify whether German compassionate access, a US academic trial, or an emerging Chinese trial is the most accessible pathway. We coordinate records submission, hospital contact, and logistics — exactly as we do for cancer CAR-T.

China's leadership in CAR-T volume and manufacturing capacity is extending into autoimmune disease. Several major centres launched or are planning autoimmune CAR-T programmes in 2025–2026.

• PUMCH Beijing

  Peking Union Medical College Hospital's rheumatology and haematology departments have initiated anti-CD19 CAR-T feasibility studies for refractory SLE and inflammatory myositis. Programme is in early patient enrolment phase as of 2026.

• Shanghai Centres

  Ruijin Hospital and Zhongshan Hospital in Shanghai are exploring autoimmune indications within their broader CAR-T programmes. Shanghai's cell therapy infrastructure — already the most developed in Asia — enables rapid programme expansion.

• Why China Is Emerging as an Access Option

  Lower manufacturing costs, shorter regulatory timelines for academic trials, and China's existing international patient infrastructure make Chinese autoimmune CAR-T trials increasingly accessible for patients from Asia and the Middle East — particularly those who cannot afford or access German or US programmes.

• CancerFax China Autoimmune Pathway

  CancerFax monitors Chinese autoimmune CAR-T trial enrolment status. When a patient with refractory SLE, MG, or scleroderma is ineligible for or cannot access German/US programmes, CancerFax can initiate a China-access review with the relevant centre.

Continue exploring CAR-T for autoimmune disease — from the main overview to side-effect management and access options.

Frequently Asked Questions — Autoimmune CAR-T